Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of British Columbia

$58,375.00

Hydrogel-based microfluidic cell culture system for controlled drug dosage effects

FY 2012-13

Summary
OBJECTIVE: This project will develop a microfluidic system to culture, characterize, image, and screen cells within a single automated, portable platform, with large potential impact to improve cell-based drug screening. BACKGROUND: The 2-D monolayer-based method of cell culture is well established in molecular and cell biology. Recently, there has been increased interest in 3-D cell culture, in which cells are embedded in a material that mimics the ECM. Interaction between cells and the ECM in vivo regulates differentiation, migration, and many other functions. As a cancer model, the tissue culture environment can have a dramatic influence on cell behaviour, such as modified morphology, gene expression, and proliferation. This phenomenon will have a crucial impact in the pharmacological response of a tumour cell to therapeutic agents. Thus, drugs developed using a 2-D screening system may not subsequently have the same activity against solid tumours, contributing to the high attrition rate in drug development. APPROACH: As a new paradigm for cell-based testing, this microscale platform will address a gap between in vitro and animal models by providing a simple, scalable tool to apply standardized protocols used in cellular response assays. This research will combine a hydrogel-based method 3-D of culturing cells with on-chip microfluidic flow control for precise fluid handling. Breast tumour cells will be seeded into an array of chambers where they can form tumour-like aggregates. We will use this system will to conduct controlled, repeated treatments and monitoring of the effects of therapeutic drugs and drug combinations on the cells. We will use the on-chip mixing and fluid handling capability to recreate more realistic pharmacokinetic profiles of compounds to examine the relationship between dose and concentration with response. The use of transparent materials allows the integration of these chips onto high-throughput imaging systems, with advantages in speed, cost, and efficiency. This platform will thus provide a means to assess the impact of treatment standards as well as new treatments designed to achieve more personalized therapy.
Program
Collaborative Health Research Projects
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
398613-2011
Name nom
Cheung, Karen
Department département
Electrical and Computer Engineering
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
58375
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
2
Nb partie
3
Application title
Hydrogel-based microfluidic cell culture system for controlled drug dosage effects
Keyword
NSERC
Application summary
OBJECTIVE: This project will develop a microfluidic system to culture, characterize, image, and screen cells within a single automated, portable platform, with large potential impact to improve cell-based drug screening. BACKGROUND: The 2-D monolayer-based method of cell culture is well established in molecular and cell biology. Recently, there has been increased interest in 3-D cell culture, in which cells are embedded in a material that mimics the ECM. Interaction between cells and the ECM in vivo regulates differentiation, migration, and many other functions. As a cancer model, the tissue culture environment can have a dramatic influence on cell behaviour, such as modified morphology, gene expression, and proliferation. This phenomenon will have a crucial impact in the pharmacological response of a tumour cell to therapeutic agents. Thus, drugs developed using a 2-D screening system may not subsequently have the same activity against solid tumours, contributing to the high attrition rate in drug development. APPROACH: As a new paradigm for cell-based testing, this microscale platform will address a gap between in vitro and animal models by providing a simple, scalable tool to apply standardized protocols used in cellular response assays. This research will combine a hydrogel-based method 3-D of culturing cells with on-chip microfluidic flow control for precise fluid handling. Breast tumour cells will be seeded into an array of chambers where they can form tumour-like aggregates. We will use this system will to conduct controlled, repeated treatments and monitoring of the effects of therapeutic drugs and drug combinations on the cells. We will use the on-chip mixing and fluid handling capability to recreate more realistic pharmacokinetic profiles of compounds to examine the relationship between dose and concentration with response. The use of transparent materials allows the integration of these chips onto high-throughput imaging systems, with advantages in speed, cost, and efficiency. This platform will thus provide a means to assess the impact of treatment standards as well as new treatments designed to achieve more personalized therapy.
University of British Columbia - $58,375 Grant (2012-… | Canada Spends